All In Biotech

Drug Trial Radar · NCT07519330

Clinical Study to Evaluate the Efficacy and Safety of HH-006 in Patients With Chronic Hepatitis B Virus Infection

Phase II Clinical Study to Evaluate the Efficacy and Safety of Multiple Dosing of HH-006 in Patients With Chronic Hepatitis B Virus Infection

Last checked: Nov 19, 2026Latest source record: Jun 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

45

Planned (sponsor's estimate)

Start

May 14, 2026

Primary completion

Feb 28, 2028

Study completion Mar 22, 2028

Sponsor

Lead sponsor
Huahui HealthIndustry
Sponsor type
Industry
First posted
Apr 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study HH006-202 is designed to assesses the efficacy and safety of HH-006 in adults chronic HBV infection. Eligible participants will receive study treatment for 48 weeks. All treated patients will also undergo a follow-up period after last study drug treatment.

Conditions

  • Chronic Hepatitis B Virus Infection

Interventions

  • HH-006Biological

    HH-006 480 mg SC injection every one week for 4 weeks and followed by 240 mg QW for 44 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. HBsAg change from baselineTime frame: week 24

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Chongqing University Three Gorges Hospital

    Chongqing, Chongqing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.